gsk1482160
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00849134)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- P2X purinoceptor 7NEGATIVE ALLOSTERIC MODULATOR
P2RX7 negative allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl- Mol. weight
- 334.73 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545206 ↗
- ChEMBLCHEMBL1222883 ↗
Also known as
- gsk1482160
- gsk1482160
- gsk1482160
- gsk1482160
- n-(2-chloro-3-(trifluoromethyl)benzyl)-n-methyl-5-oxopyrrolidine-2-carboxamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00849134 | Phase 1 | Nov 1, 2008 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1